Statement of financial position of PolyPeptide Group AG

As at 31 December

Assets, kCHF

Note

2024

2023

 

 

 

 

Current assets

 

 

 

Cash and cash equivalents

1

224

280

Loan to group companies

 

65,459

Other receivables from group companies

 

40,479

17,799

Accrued income and prepaid expenses

 

691

683

Total current assets

 

106,853

18,762

 

 

 

 

Non-current assets

 

 

 

Loan to group companies

 

126,575

222,137

Financial assets

3

5,221

5,434

Investments

2

851,700

525,300

Tangible assets

 

586

683

Total non-current assets

 

984,082

753,554

 

 

 

 

Total assets

 

1,090,935

772,316

Statement of financial position of PolyPeptide Group AG (continued)

As at 31 December

Liabilities, kCHF

Note

2024

2023

 

 

 

 

Current liabilities

 

 

 

Other liabilities due to third parties

 

1,354

1,471

Interest-bearing liabilities due to shareholder

 

28,730

37,812

Accrued expenses and deferred income

 

36

134

Total short-term liabilities

 

30,120

39,417

 

 

 

 

Non-current liabilities

 

 

 

Interest-bearing liabilities due to third parties

 

37,647

46,301

Total long-term liabilities

 

37,647

46,301

 

 

 

 

Shareholders' equity

 

 

 

Share capital

4

331

331

Statutory capital reserves

 

 

 

Reserves from capital contribution

5

2,104,803

2,104,803

Other capital reserves

 

4,949

4,949

Treasury shares

6

-9,043

-10,943

Net loss brought forward

 

-1,412,542

-1,173,235

Net loss on sale of treasury shares

 

-1,102

Net gain/loss for the year

 

335,772

-239,307

Total shareholders' equity

 

1,023,168

686,598

 

 

 

 

Total liabilities and shareholders' equity

 

1,090,935

772,316